Relay Pharma - Wutah bathi EPS kuartalan RLAY

Relay Therapeutics' experienced management leverages advanced AI technologies to develop precision oncology drugs. This chart on GURU.Markets displays the quarterly growth of net income per share, where the 13.40 mark indicates the current trend level. The asset's value growth is supported by the success of RLY-2608 trials and a significant capital reserve for further development.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan relaytx.com (RLAY): kanggo periode 04.07.2022 - 12.11.2026

Rincian analitis perusahaan Relay Therapeutics

- rega saham lan konsensus proyeksi valuasi:

Kutipan saham Relay Therapeutics, Inc.|RLAY - Rega prakiraan analis

- rincian nilai pasar emiten:

Kapitalisasi pasar Relay Pharma|RLAY - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Relay Therapeutics|RLAY - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku relaytx.com|RLAY - Aset Neraca Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Relay Therapeutics|RLAY - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Relay Therapeutics|RLAY - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Relay Pharma|RLAY - Utang jangka dawa|Utang jangka cendhak perusahaan Relay Therapeutics|Indikator likuiditas cepet relaytx.com

- rincian bathi lan kelipatan pasar:

RLAY - Bathi pungkasan|Bathi mangsa ngarep Relay Therapeutics|RLAY - Rasio rega pasar marang bathi resik|Pangali Forward P/E Relay Pharma|RLAY - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Relay Pharma|RLAY - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Relay Therapeutics|RLAY - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan relaytx.com|RLAY - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Relay Therapeutics

Pambiji fundamental perusahaan:Relay Therapeutics, Inc. - RLAY

This indicator measures the dynamics of net earnings per share compared to the same period last year. By analyzing the quarterly shift in earnings per share, an investor determines the business scaling rate and the risk of asset overvaluation. For Relay Therapeutics (RLAY), this metric reflects the cost efficiency of energy-intensive supercomputers used in drug modeling. The stability of this metric confirms the resilience of the operating model, while sharp fluctuations signal a shift in market expectations.

Analisis perusahaan pesaing